araag2/HINT huggingface dataset:
Clinical trial NCT01118962 (phase 2, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject completed the SP0961 (NCT01118949) study

          -  Subject is expected to benefit from participation in an open-label extension study
             with Lacosamide, in the opinion of the investigator

        Exclusion Criteria:

          -  Subject meets the withdrawal criteria for SP0961 (NCT01118949) or is experiencing an
             ongoing Serious Adverse Event (SAE)
Clinical trial NCT00128440 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: bea 2180 br, tiotropium
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        1. Patients must have relatively stable, moderate to severe airway obstruction with an
             FEV1 >=30% and <= 60% of predicted normal and FEV1 <=70% of FVC at the baseline PFTs
             at Visit 1 (at both timepoints).

          2. All patients must have an increase in FEV1 of at least 12% from baseline (th e -10
             minute measurement) 45 min after inhalation of 80 ?g Atrovent MDI.

          3. Male or female patients 40 years of age or older.

          4. Smoker or ex-smoker with a history of more than 10 pack years.

        1. Patients with any other significant disease will be excluded. 2. Patients with a history
        of asthma or allergic rhinitis will be excluded.
Clinical trial NCT00501891 (phase 2, status: completed)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: bevacizumab, metronomic temozolomide
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically confirmed diagnosis of WHO grade IV primary
             malignant glioma

          -  Karnofsy Performance Status (KPS) >/= 60%

          -  Evidence of measurable primary CNS neoplasm on contrast-enhanced MRI.

          -  An interval of at least 4 weeks between prior surgical resection or 1 week from a
             biopsy and enrollment on this protocol

          -  An interval of at least 4 weeks from the end of prior radiotherapy or one week from
             the end of a cycle of chemotherapy and enrollment on this protocol.

          -  No evidence of CNS hemorrhage on the baseline MRI or CT scans

        Exclusion Criteria:

          -  Life expectancy < 8 weeks

          -  Pregnancy or breast feeding

          -  Progression to metronomic temozolomide, defined as tumor progression while taking
             daily temozolomide or progression within 4 weeks of stopping metronomic temozolomide

          -  Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or
             diastolic blood pressure > 100 mmHg on antihypertensive medications)
Clinical trial NCT00166296 (phase 2, status: completed)
Conditions: major depressive disorder, hepatitis c, chronic
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: escitalopram, placebo
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with chronic hepatitis C who are going to initiate treatment with
             peginterferon alfa2a + ribavirin.

          -  Age 18-65 years.

          -  Signed informed consent.

          -  If female, they are not in fertile period or they use barrier contraceptives.

          -  Patients able to understand and fill written questionnaires.

        Exclusion Criteria:

          -  Hepatic cirrhosis or carcinoma.

          -  Less than 4000/mm3 leucocytes, or less than 70000/mm3 platelets.

          -  Hemoglobin less than 11 g/dL (females) or 12 (males).

          -  Any risk factor for hemolysis.

          -  Comorbid severe medical conditions (kidney, immune system, lung, heart, thyroid, etc).

          -  Baseline mental disorders that require antidepressants (depressive disorders and
             anxiety disorders).

          -  Other baseline mental disorders (delirium, substance use disorders).

          -  Mental disorders at any time (dementia, psychotic disorders, bipolar disorders.

          -  Contraindications of escitalopram (hypersensibility, diabetes, patients using
             serotoninergic agents, drugs that enhance the risk of bleeding, or monoamineoxidase
             inhibitors -MAOIs-).
Clinical trial NCT00618540 (phase 2, status: terminated)
Conditions: histiocytosis, langerhans-cell
ICD codes: C96.6, C96.5, C96.0, J84.82
Drugs: fludarabine phosphate, melphalan
SMILES: NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed Langerhans cell histiocytosis (LCH) by demonstration of CD1a
             positivity or Birbeck granules in lesions

          -  Considered poor-risk, defined as multisystem disease with involvement of one or more
             risk organs (i.e., liver, spleen, lungs, and/or hematopoietic system)

               -  No isolated "lung only" LCH

          -  Progressive disease after one of the following treatments:

               -  LCH-III protocol or other standard LCH-directed therapies

               -  At least 1 course of the current salvage protocol (i.e., LCH-2 2005) or similar
                  therapy (e.g., cytosine arabinoside or cladribine-based regimens)

          -  HLA-matched related or unrelated donor OR unrelated umbilical cord blood (UCB)
             available

               -  1 locus mismatch for donor allowed

               -  Up to 2 loci mismatch for unrelated UCB allowed

          -  Any hematologic status (transfusion support allowed)

          -  Adequate hepatic, renal, cardiac, and pulmonary function to undergo reduced-intensity
             hematopoietic cell transplantation (RI-HCT) including the following:

               -  Transaminases < 5 times upper limit of normal (ULN)

               -  Bilirubin < 3 times ULN (unless secondary to hepatic LCH)

               -  Creatinine ≤ 2 mg/dL (adults) (if creatinine > 1.2 OR history of renal
                  dysfunction, must have estimated creatinine clearance > 40 mL/min)

               -  Creatinine clearance > 40 mL/min (pediatrics)

               -  Glomerular filtration rate ≥ 50mL/min

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Decompensated congestive heart failure, uncontrolled arrhythmia, or left ventricular
             ejection fraction ≥ 35%

          -  Pulmonary failure (i.e., requiring mechanical ventilation) unless secondary to active
             underlying LCH

          -  Isolated liver sclerosis or pulmonary fibrosis unless secondary to active underlying
             LCH

          -  Uncontrolled active life-threatening infection

          -  Pregnant or nursing

          -  Less than 4 weeks after last attempted salvage chemotherapy treatment

          -  Other concurrent chemotherapy agents (e.g., methotrexate) during entire
             transplantation period up to day 100 post-transplantation
Clinical trial NCT01271777 (phase 2, status: completed)
Conditions: insulin resistance, abdominal obesity
ICD codes: Z16.11, Z16.21, D68.51, Z16.20, Z16.24, Z16.22, Z16.23, A42.1, G43.D1, I77.811, R10.815, R10.816, R10.817, R10.84
Drugs: gft505 80mg, placebo
SMILES: CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Waist circumference ≥94cm.

          -  Body Mass Index ≤ 45kg/m2.

          -  Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) > 3.

        Exclusion Criteria:

          -  Blood Pressure > 160 / 95 mmHg.

          -  Diabetes mellitus 1 or 2.

          -  Historical of bariatric surgery.

          -  Patient treated with a lipid-decreasing medication.

          -  A fasting plasma triglycerides concentration > 400mg/dL or a plasma Low Density
             Lipoprotein Cholesterol (LDL-c)concentration > 220mg/dL.
Clinical trial NCT00335868 (phase 2, status: unknown status)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: danusertib
SMILES: CO[C@@H](C(=O)N1CC2=C(C1)C(NC(=O)C1=CC=C(C=C1)N1CCN(C)CC1)=NN2)C1=CC=CC=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy

               -  Chronic, accelerated, or blastic phase disease

          -  May have T315I mutation in BCR-ABL kinase

          -  Relapsed after prior imatinib mesylate or c-ABL therapy

          -  No CNS leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week)

          -  Transaminases ≤ 2.5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

          -  Creatinine ≤ 1.5 times ULN

          -  No known history of HIV infection

          -  No active uncontrolled infection

          -  No grade 3 or 4 bleeding

          -  LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography

          -  No medical or psychiatric condition or laboratory abnormalities that would limit study
             compliance or increase risk during study participation

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 90 (female) or 180
             (male) days after completion of study treatment

          -  No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable
             angina) within the past 6 months

          -  No major thromboembolic event within the past 6 months, including any of the
             following:

               -  Myocardial infarction

               -  Stroke

               -  Transient ischemic attack

               -  Pulmonary embolism

               -  Noncatheter-related deep-vein thrombosis

        PRIOR CONCURRENT THERAPY:

          -  Recovered from all acute toxic effects (excluding alopecia) of prior therapy

          -  More than 2 weeks since prior chemoimmunotherapy

               -  Hydroxyurea must be discontinued 1 day prior to study therapy

          -  More than 4 weeks since prior major surgery

          -  No other concurrent approved or investigational anticancer treatment, including
             chemotherapy, biologic response modifiers, hormones, or immunotherapy

          -  No other concurrent investigational drugs

          -  No concurrent participation in another treatment clinical trial
Clinical trial NCT00377559 (phase 2, status: completed)
Conditions: breast cancer, neoplasm metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: non pegylated liposomal doxorubicin and docetaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women with histologically documented metastatic or locally advanced metastatic
             HER2/neu negative breast cancer.

          -  In the case of previous adjuvant or neoadjuvant chemotherapy with anthracyclines or
             taxanes, this must have been completed more than 12 months before inclusion.

          -  In the case of previous adjuvant or neoadjuvant chemotherapy, cumulative anthracycline
             dose ≤ 360 mg/m2 of doxorubicin or 600 mg/m2 of epirubicin or 75 mg/m2 of mitoxantrone
             on inclusion.

          -  Previous endocrine therapy is authorized (endocrine therapy other than goserelin must
             be stopped before starting treatment).

          -  Previous radiotherapy is authorized, if discontinued ≥ 4 weeks prior to inclusion in
             the study and if < 10% of the bone marrow was within the irradiated area.

          -  Age ≥ 18 years.

          -  Performance status 0,1, or 2.

          -  Life expectancy ≥ 3 months.

          -  Evaluable disease.

          -  Normal LVEF (multigated acquisition [MUGA] scan or echocardiography).

          -  Normal haematological, hepatic and renal parameters: neutrophils ≥ 1.5 x 10^9/l;
             platelets ≥ 100 x 10^9/l; hemoglobin (Hb) ≥ 6 mmol/L; total bilirubin ≤ 1.5 times the
             upper limit of normal (ULN); transaminases ≤ 2.5 x ULN; alkaline phosphatase ≤ 2.5 x
             ULN; creatinine ≤ 1.5 x ULN.

          -  Dated and signed written informed consent.

        Exclusion Criteria:

          -  Previous chemotherapy for metastatic disease.

          -  History of other cancer, except for cervical carcinoma in situ treated by cone
             resection or basal cell or squamous cell skin cancer.

          -  History of congestive heart failure or myocardial infarction ≤ 1 year; cardiac
             function: NYHA ≥ 2 or LVEF < 50%. Uncontrolled significant heart disease, such as
             unstable angina.

          -  Poorly controlled hypertension.

          -  Performance status 3, 4.

          -  Symptomatic or progressive brain metastases.

          -  Active infection or other serious underlying disease.

          -  Concomitant participation in other clinical trials.

          -  Pregnant women or nursing mothers; patients of childbearing potential without
             effective contraception.

          -  Absolute medical contraindication to the use of corticosteroid premedication.

          -  Allergy to polysorbate 80, doxorubicin, or egg lecithin.

          -  NCI-CTC grade > 1 peripheral neuropathy.

          -  Patients not able to comply with regular medical follow-up
Clinical trial NCT01155986 (phase 2, status: terminated)
Conditions: pain, chronic pain, neuropathic pain, postoperative pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3, E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610
Drugs: lidocaine 5% medicated plaster, placebo topical plaster
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    trial was stopped due to difficult enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects with >= 18 years of age

          -  Intact skin in the area of topical treatment

          -  Patients suffering from moderate to severe ( 5 or more points on an 11 point Numerical
             Rating Scale where 10 is the worst possible pain, and 0 indicates no pain) chronic
             daily postoperative neuropathic pain for the past 6 to 24 months.

          -  Patients should have symptoms for example allodynia (a pain due to a stimulus which
             does not normally provoke pain); and or dysesthesia (unpleasant, abnormal sense of
             touch).

        Exclusion Criteria:

          -  Contraindications to lidocaine 5% medicated plaster, or paracetamol

          -  Evidence or history of alcohol, medication or drug abuse and/or dependency in the past
             3 years.

          -  Evidence or history (during the past 3 years) of epilepsy, neurotic personality,
             psychiatric illness, or suicide risk.

          -  Pregnant or breastfeeding women

          -  Women of childbearing potential who are sexually active without satisfactory
             contraception for at least 28 days prior to enrollment, during the trial, and until 28
             days after the follow-up visit.

          -  Severe renal, hepatic or heart disorder.

          -  Surgery in the past 3 months before screening.

          -  Anticipated need for surgery during the trial, requiring at least regional or general
             anesthesia.

          -  Pending litigation due to chronic pain or disability.

          -  Participation in another trial of investigational medicinal products or devices
             parallel to or less than 1 month before entry into the trial, or previous
             participation in this trial.

          -  Presence of other severe pain that could confound the assessment or self- evaluation
             of the localized postoperative neuropathic pain.

          -  For patients with chronic postoperative neuropathic pain related to a surgery due to
             tumors: suspected residual tumor or metastases, chemotherapy or radiotherapy for
             treatment of tumor(s).

          -  Total anesthesia in the area of localized chronic pain
Clinical trial NCT01066715 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: xoma 052, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with T2D (disease duration ≥ 6 months)

          -  HbA1c ≥ 6.8% and ≤ 10.0%

          -  Have been on a stable regimen of metformin monotherapy for at least 12 weeks prior to
             Day 0

          -  Willingness to maintain stable diet and exercise regime throughout the study

          -  Willingness to maintain current doses/regimens of vitamins and dietary supplements
             through the end of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  History of malignancy within 5 years

          -  History of allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  Advanced stage heart failure (New York Heart Association [NYHA] class 3 or 4)

          -  Clinically significant uncontrolled arrhythmias

          -  History of tuberculosis

          -  Active leg, foot, or decubitus ulcer

          -  Any significant inflammatory, rheumatologic, or systemic autoimmune disease

          -  History of chronic infections

          -  History or any symptoms of a demyelinating disease

          -  Major surgery within 3 months

          -  Female subjects who are pregnant, planning to become pregnant

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00504504 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, adriamycin, bleomycin, vinblastine, dacarbazine (dtic)
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C, N[C@@H](CCCNC(N)=N)C(O)=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Hodgkin's disease patients who relapse after radiation therapy alone and previously
             untreated patients with stage II bulky, III and IV who are eligible for ABVD.

          2. Must have histologically proven diagnosis of Hodgkin's disease (Nodular sclerosis or
             mixed cellularity).

          3. Must have bidimensionally measurable disease.

          4. Must sign a consent form.

          5. Must be older than 16 years of age.

          6. Must have adequate bone marrow reserve (ANC > 1,000/microL, Platelet > 100,000/microL

          7. Left Ventricular Ejection Fraction (LVEF) >/= 50% by multigated acquisition (MUGA)
             scan or echocardiogram.

          8. Serum creatinine < 2 mg/dl, serum bilirubin < 2 mg/dl

        Exclusion Criteria:

          1. HIV positive.

          2. Pregnant women and women of child bearing age who are not practicing adequate
             contraception.

          3. Prior chemotherapy.

          4. Severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and
             asthma.
Clinical trial NCT00582166 (phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ibritumomab tiuxetan (zevalin) + rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    see 'limitations and caveats' section
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3

          -  Meeting FLIPI criteria for intermediate or high risk.

          -  No prior chemotherapy, radiotherapy or immunotherapy for lymphoma;

          -  Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen
             positive.

        Exclusion Criteria:

          -  May not be pregnant or breastfeeding, have documented CNS (Central Nervous System)
             disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF
             (Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior
Clinical trial NCT00265304 (phase 2, status: completed)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: ketoprofen
SMILES: CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who completed Study 17-007 or discontinued from Study 17-007 due to lack of
             efficacy

          -  Patients who did not complete or discontinue from Study 17-007 must have
             osteoarthritis of both knees for a minimum of six months

          -  Have moderate pain in the most involved knee when not taking non-steroidal
             anti-inflammatory drugs (NSAIDs)

          -  Must have used an oral NSAID on at least three days per week for the last three
             months, or 25 of the 30 days before screening

          -  Demonstrate x-ray evidence of osteoarthritis in the most involved knee during the last
             six months

        Exclusion Criteria:

          -  Any patient currently receiving physical therapy to either knee or having a history of
             allergy, hypersensitivity or contraindication to ketoprofen, naproxen, or
             acetaminophen, an NSAID idiosyncrasy, or any other medical condition that would
             compromise the ability of the subject to complete the required assessments and visits

          -  For patients who did not participate in Study 17-007: having Grade 1 or Grade 4
             severity of the most involved knee based on x-ray criteria

          -  Received intra-articular injections or arthroscopy of the most involved knee during
             three months before screening visit

          -  Have a large bulging effusion, or have inflammation of the most involved knee that
             could be related to gout, pseudogout-induced synovitis, or infection

          -  Have a history of partial or total knee replacement in either knee, or have a history
             of gout, pseudo-gout induced synovitis, or infection of the more severe knee